Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P04899
UPID:
GNAI2_HUMAN
Alternative names:
Adenylate cyclase-inhibiting G alpha protein
Alternative UPACC:
P04899; B3KTZ0; B4DYA0; B4E2X5; Q6B6N3; Q8IZ71
Background:
The Guanine nucleotide-binding protein G(i) subunit alpha-2, also known as Adenylate cyclase-inhibiting G alpha protein, plays a pivotal role in cellular signaling. It modulates transmembrane signaling systems by acting as a transducer or modulator. Specifically, it inhibits adenylate cyclase in response to beta-adrenergic stimuli, which is crucial for hormonal regulation. Additionally, it regulates the cell surface density of dopamine receptors DRD2 by sequestering them as an intracellular pool, indicating its role in neurotransmitter regulation.
Therapeutic significance:
Understanding the role of Guanine nucleotide-binding protein G(i) subunit alpha-2 could open doors to potential therapeutic strategies. Its involvement in modulating transmembrane signaling and neurotransmitter regulation presents it as a target for developing treatments for disorders related to these pathways.